PAP
SMMT icon

Persistent Asset Partners’s Summit Therapeutics SMMT Stock Holding History

Persistent Asset Partners’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$223K Buy
+15,312
New +$272K 0.07% 201
2025
Q3 		– Sell
-331
Closed -$8.03K – 300
2025
Q2 		$7.04K Buy
+331
New +$7.55K 0.01% 172

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Persistent Asset Partners's SMMT Position: Q2 2026 in Review

Persistent Asset Partners opened a new position in Summit Therapeutics (SMMT) in Q2 2026: 15,312 shares worth $223K. The stake represents 0.07% of the portfolio and ranks #201 among its holdings. This is a return to the name: Persistent Asset Partners previously reported a position in SMMT as recently as Q2 2025.

Persistent Asset Partners first reported a position in SMMT in Q2 2025 and has held it in 2 quarters since. 243 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Persistent Asset Partners held 15,312 shares of Summit Therapeutics worth $223K as of Q2 2026.
  • Summit Therapeutics was a new Persistent Asset Partners position in Q2 2026.
  • Summit Therapeutics made up 0.07% of Persistent Asset Partners's portfolio in Q2 2026, its #201 holding.
  • Persistent Asset Partners first reported a position in Summit Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • 243 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.